Business
FIRST PATIENT DOSED IN AT278 CLINICAL TRIAL
FIRST PATIENT DOSED IN AT278 CLINICAL TRIAL.
About this update from Arecor Therapeutics Plc
[{"type":"text","content":"\n \n \n \n Arecor Therapeutics plc\n \n \n \n (\"Arecor\" or the \"Group\")\n \n \n \n \n \n \n \n \n FIRST PATIENT DOSED IN SECOND PHASE I CLINICAL TRIAL OF AT278 ULTRA-CONCENTRATED, ULTRA-RAPID ACTING INSULIN CANDIDATE\n \n \n \n \n \n \n \n \n - Disrupter insulin with potential to be the first ultra-concentrated and ultra-rapid acting insulin available for patients\n \n \n - AT278 aims to significantly improve post prandial glucose control and reduce injection volume and potentially enable fewer injections per day for people with Type 2 diabetes who have high insulin needs\n \n \n - Ultra-concentrated, ultra-rapid acting insulin such as AT278 is critical to development of next generation miniaturised insulin delivery devices\n \n \n - Trial expected to complete in Q4 2023\n \n \n \n \n \n \n \n \n Cambridge, UK, 22 March\n 2023:\n \n Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today's therapies to enable healthier lives, today\n announces that the first patient has been dosed in its Phase I clinical trial investigating AT278,\n an ultra-rapid acting, ultra-concentrated (500 U/mL) insulin candidate\n , in Type 2 diabetic patients, the primary target population.\n \n \n \n \n \n The trial is a double blind, randomised, crossover study comparing the\n pharmacokinetic (PK) and pharmacodynamic (PD)\n profile following a single subcutaneous dose of 0.5 U/Kg of AT278 (500 U/mL) with NovoRapid® (100 U/mL) in 32 people with Type 2 diabetes in a euglycemic clamp setting. In addition, the PK/PD profile following a single subcutaneous dose of 0.5 U/Kg Humulin-R U500® will be evaluated in each of the participants. The trial, which is expected to complete within Q4 2023, is being conducted at the Medical University of Graz, Austria, an expert clinical research facility in metabolic diseases research and euglycaemic clamp methodology, with Professor Thomas Pieber as the trial's Principal Investigator.\n \n \n \n \n \n \n Sarah Howell, Chief Executive Officer at Arecor, said:\n \n \n \"Having already demonstrated AT278's very promising profile\n \n \n in Type 1 diabetes patients, we look forward to furthering our understanding of its potential impact in Type 2 diabetes patients, the primary target market for this potential insulin treatment.\n \n \n \...